| Leukeran (chlorambucil) / GSK |
ChiCTR2000041420: A randomized, open label, multicenter study of ibotinib monotherapy versus ibotinib combined with nitrogen mustard in the first-line treatment of chronic lymphocytic leukemia / small lymphocytic lymphoma |
|
|
| Recruiting | 4 | 300 | | Ibrutinib monotherapy ;Ibrutinib plus chlorambucil | Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, Investigator-sponsored | Chronic lymphocytic leukemia/small lymphocytic lymphoma | | | | |
| Active, not recruiting | 3 | 445 | Europe, Canada, US, RoW | Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva | Hoffmann-La Roche, AbbVie, German CLL Study Group | Lymphocytic Leukemia, Chronic | 08/18 | 08/25 | | |
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 3 | 535 | Europe, Canada, US, RoW | Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 02/19 | 09/25 | | |
|
|
|
|
|
|
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 211 | Europe, Canada, US, RoW | Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy) | Janssen Research & Development, LLC, Pharmacyclics LLC. | Leukemia, Lymphocytic, Chronic, B-Cell | 02/21 | 04/29 | | |
|
|
|
| Terminated | 3 | 603 | Europe, US, RoW | Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran | TG Therapeutics, Inc. | Chronic Lymphocytic Leukemia | 02/23 | 02/23 | | |
|
|
|
|
|
|
|
|
NCT01724346 / 2012-003968-44: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Completed | 3 | 269 | Europe, Canada, US, RoW | Ibrutinib, PCI-32765, Next-line ibrutinib | Pharmacyclics LLC., Janssen Research & Development, LLC | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 08/23 | | |
NCT06319456: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
|
|
| Recruiting | 3 | 344 | RoW | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | Ascentage Pharma Group Inc. | CLL/SLL | 08/27 | 08/28 | | |
D822BC00001, NCT04075292: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 155 | RoW | Acalabrutinib, Rituximab, Chlorambucil | AstraZeneca | Untreated Chronic Lymphocytic Leukemia | 01/24 | 03/25 | | |
|
|
|
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Active, not recruiting | 2 | 112 | Europe | Chlorambucil, Rituximab i.v., Rituximab s.c. | International Extranodal Lymphoma Study Group (IELSG) | MALT Lymphoma | 03/16 | 09/28 | | |
2020-002949-42: Study on chlorambucil efficacy in patients with metastatic pancreatic adenocarcinoma already undergoing previous chemotherapy treatment and carriers of a BRCA mutation or other mutations concerning the genes involved in DNA repair. Studio sull’efficacia del trattamento del clorambucile in pazienti affetti da adenocarcinoma del pancreas metastatico già sottoposti a precedente trattamento chemioterapico e portatori di una mutazione BRCA o di altre mutazioni riguardanti i geni coinvolti nel riparo del DNA. |
|
|
| Not yet recruiting | 2 | 30 | Europe | Leukeran, [024790026], Film-coated tablet, LEUKERAN - 2 MG COMPRESSE RIVESTITE CON FILM 25 COMPRESSE | OSPEDALE SAN RAFFAELE, Fondi Liberi dell' Oncologia Medica dell'Ospedale San Raffaele | Patients affected by metastatic pancreatic adenocarcinoma (PDAC). Pazienti affetti da adenocarcinoma del pancreas (PDAC) metastatico., Metastatic pancreatic adenocarcinoma patients Pazienti con tumore del pancreas in stadio avanzato (metastatico)., Diseases [C] - Cancer [C04] | | | | |
SALE, NCT04692740: Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations ( Trial) |
|
|
| Active, not recruiting | 2 | 20 | Europe | Chlorambucil, Oral, 2 Mg | Michele Reni | Pancreatic Ductal Adenocarcinoma | 01/23 | 12/23 | | |
| Recruiting | N/A | 104 | RoW | | Healthy Future | Chronic Lymphocytic Leukemia | 08/24 | 04/25 | | |
